New hope for kids with tough cancers: experimental drug SGT-53 under study
NCT ID NCT02354547
First seen May 12, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study tests an experimental drug called SGT-53 in children and young adults (ages 1 to 21) with solid tumors that have returned or not responded to standard treatments. The goal is to find the safest dose of SGT-53 when given alone and with chemotherapy drugs topotecan and cyclophosphamide. Researchers will monitor side effects to determine the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.